Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
PharmaCyte Biotech, Inc. entered into Engagement Letter with Katalyst Securities LLC valued at cash fee equal to 6% of gross proceeds (effective 2023-05-09).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Katalyst Securities LLC
- Value
- cash fee equal to 6% of gross proceeds
- Effective
- 2023-05-09
Exact text from the filing
In connection with the Private Placement, pursuant to an Engagement Letter, dated May 9, 2023, between the Company and Katalyst Securities LLC (the “Placement Agent”), the Company has agreed to pay the Placement Agent a cash fee equal to 6% of the gross proceeds from any sale of securities in the Private Placement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
PharmaCyte Biotech, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate gross proceeds of approximately $35 million (effective 2023-05-09).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- aggregate gross proceeds of approximately $35 million
- Effective
- 2023-05-09
Exact text from the filing
On May 9, 2023, PharmaCyte Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors (i) an aggregate of 35,000 shares of the Company’s newly-designated Series B convertible preferred stock with a stated value of $1,000 per share, initially convertible into up to 8,750,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a conversion price of $4.00 per share (the “Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 8,750,000 shares of Common Stock (the “Warrants”) (collectively, the “Private Placement”).
View on SEC.gov